Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
Aligos Therapeutics (Nasdaq: ALGS) announced that eight abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025, scheduled for May 7-10, 2025 in Amsterdam. The presentations focus on two key drug candidates:
1. ALG-000184: A potential first/best-in-class small molecule CAM-E for chronic hepatitis B virus infection, with three abstracts highlighting its profound HBV DNA suppression in 96-week studies and resistance barrier analysis.
2. ALG-055009: A potential best-in-class thyroid hormone receptor beta agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), with four abstracts demonstrating significant reductions in atherogenic lipids and liver fat, including studies in combination with GLP-1 receptor agonists.
Aligos Therapeutics (Nasdaq: ALGS) ha annunciato che otto abstract sono stati accettati per la presentazione al Congresso della European Association for the Study of the Liver (EASL) 2025, in programma dal 7 al 10 maggio 2025 ad Amsterdam. Le presentazioni si concentrano su due principali candidati farmaci:
1. ALG-000184: una possibile molecola CAM-E di prima/classe migliore per l'infezione cronica da virus dell'epatite B, con tre abstract che evidenziano la sua profonda soppressione del DNA HBV in studi di 96 settimane e l'analisi della barriera alla resistenza.
2. ALG-055009: un potenziale agonista del recettore beta degli ormoni tiroidei di classe migliore per la steatoepatite associata a disfunzione metabolica (MASH), con quattro abstract che mostrano significative riduzioni dei lipidi aterogenici e del grasso epatico, inclusi studi in combinazione con agonisti del recettore GLP-1.
Aligos Therapeutics (Nasdaq: ALGS) anunció que ocho resúmenes han sido aceptados para presentación en el Congreso de la Asociación Europea para el Estudio del Hígado (EASL) 2025, programado del 7 al 10 de mayo de 2025 en Ámsterdam. Las presentaciones se centran en dos candidatos principales a fármacos:
1. ALG-000184: una posible molécula CAM-E de primera/clase líder para la infección crónica por el virus de la hepatitis B, con tres resúmenes que destacan su profunda supresión del ADN del VHB en estudios de 96 semanas y análisis de la barrera a la resistencia.
2. ALG-055009: un potencial agonista del receptor beta de la hormona tiroidea de clase líder para la esteatohepatitis asociada a disfunción metabólica (MASH), con cuatro resúmenes que demuestran reducciones significativas en lípidos aterogénicos y grasa hepática, incluyendo estudios en combinación con agonistas del receptor GLP-1.
Aligos Therapeutics (나스닥: ALGS)는 2025년 5월 7일부터 10일까지 암스테르담에서 열리는 유럽 간학회(EASL) 2025에서 발표할 8개의 초록이 채택되었다고 발표했습니다. 발표는 두 가지 주요 약물 후보에 중점을 둡니다:
1. ALG-000184: 만성 B형 간염 바이러스 감염을 위한 잠재적 최초/최고급 CAM-E 소분자로, 96주간 연구에서 HBV DNA 억제 효과와 내성 장벽 분석을 강조한 세 편의 초록이 포함되어 있습니다.
2. ALG-055009: 대사 기능 장애 관련 지방간염(MASH)을 위한 잠재적 최고급 갑상선 호르몬 수용체 베타 작용제로, GLP-1 수용체 작용제와 병용한 연구를 포함해 동맥경화성 지질과 간 지방을 크게 감소시키는 네 편의 초록이 발표됩니다.
Aligos Therapeutics (Nasdaq : ALGS) a annoncé que huit résumés ont été acceptés pour présentation au Congrès de l’Association Européenne pour l’Étude du Foie (EASL) 2025, prévu du 7 au 10 mai 2025 à Amsterdam. Les présentations portent sur deux candidats médicaments clés :
1. ALG-000184 : une molécule CAM-E potentielle de première/classe meilleure pour l’infection chronique par le virus de l’hépatite B, avec trois résumés mettant en avant sa suppression profonde de l’ADN du VHB lors d’études de 96 semaines et l’analyse de la barrière à la résistance.
2. ALG-055009 : un agoniste potentiel du récepteur bêta des hormones thyroïdiennes de classe meilleure pour la stéato-hépatite associée à une dysfonction métabolique (MASH), avec quatre résumés démontrant des réductions significatives des lipides athérogènes et de la graisse hépatique, incluant des études en association avec des agonistes du récepteur GLP-1.
Aligos Therapeutics (Nasdaq: ALGS) gab bekannt, dass acht Abstracts für Präsentationen auf dem European Association for the Study of the Liver (EASL) Kongress 2025 angenommen wurden, der vom 7. bis 10. Mai 2025 in Amsterdam stattfindet. Die Präsentationen konzentrieren sich auf zwei wichtige Arzneimittelkandidaten:
1. ALG-000184: Ein potenzielles First-in-Class/Best-in-Class CAM-E Kleinmolekül zur Behandlung der chronischen Hepatitis-B-Virusinfektion, mit drei Abstracts, die die ausgeprägte HBV-DNA-Suppression in 96-Wochen-Studien und die Analyse der Resistenzbarriere hervorheben.
2. ALG-055009: Ein potenzieller Best-in-Class Agonist des Schilddrüsenhormonrezeptors Beta für die metabolisch bedingte Steatohepatitis (MASH), mit vier Abstracts, die signifikante Reduktionen atherogener Lipide und von Leberfett zeigen, einschließlich Studien in Kombination mit GLP-1-Rezeptoragonisten.
- Development of two potentially best-in-class drug candidates progressing well
- Strong 96-week efficacy data for ALG-000184 in HBV treatment
- ALG-055009 demonstrates significant therapeutic effects in MASH treatment
- High barrier of resistance shown for ALG-000184
- Both drug candidates still in clinical trial phases
- No approved products or revenue generation yet
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.
Details on the abstracts are as follows:
ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection
Abstract #: 861
Title: Monotherapy with the Novel Capsid Assembly Modulator ALG-000184 for up to 96 Weeks Results in Profound and Sustained HBV DNA Suppression in Untreated Subjects with Chronic HBV Infection
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: May 8, 2025 at 4:15pm – 5:00pm CET; May 8, 2025 at 8:30am – 5:00pm CET
Session: Poster Tour; Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
Abstract #: 856
Title: The Safety and Antiviral Effect of Oral Daily 300 mg ALG-000184 in Combination with Entecavir for up to 96 Weeks in Untreated HBeAg-Positive Subjects with Chronic Hepatitis B Virus Infection
Presenter: Professor Jinlin Hou, MD, Chairman and Professor of the Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University
Date/Time: May 8, 2025 at 8:30am – 5:00pm CET
Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
Abstract #: 1924
Title: Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184
Presenter: Andreas Jekle, PhD
Date/Time: May 8, 2025 at 8:30am – 5:00pm CET
Session: Poster - Viral Hepatitis B and D: New therapies, unapproved therapies or strategies
ALG-055009: Potential best-in-class small molecule THR-β for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Abstract #: 302
Title: ALG-055009, a novel thyroid hormone receptor beta agonist, demonstrated significant reductions in atherogenic lipids/lipoproteins, including lipoprotein (a), in patients with presumed metabolic dysfunction-associated steatohepatitis in the Phase 2a HERALD
Presenter: Stanley Wang, MD, PhD
Date/Time: May 8, 2025 at 9:45am – 10:30am CET; May 10, 2025 at 8:30am – 4:00pm CET
Sessions: Poster tour; Poster - MASLD: Therapy
Abstract #: 2185
Title: ALG-055009, a novel thyroid hormone receptor beta (THR-beta) agonist, demonstrated robust reductions in liver fat at Week 12 across subgroups including glucagon-like peptide-1 (GLP-1) receptor agonist users in non-cirrhotic MASH patients in the Phase 2a HERALD study
Presenter: Megan Fitzgerald, PhD
Date/Time: May 10, 2025 at 8:30am – 4:00pm CET
Session: Poster - MASLD: Therapy
Abstract #: 2152
Title: Population pharmacokinetic/pharmacodynamic modelling of novel thyroid hormone receptor beta agonist ALG-055009 reveals statistically significant correlation between exposure and key efficacy endpoints
Presenter: Kha Le, PhD
Date/Time: May 10, 2025 at 8:30am – 4:00pm CET
Session: Poster - MASLD: Therapy
Abstract #: 2001
Title: ALG-055009, a potent and selective thyroid hormone receptor beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis, induces pro-metabolic and anti-fibrotic gene expression in the liver of diet-induced obese mice
Presenter: Xuan Luong, PhD
Date/Time: May 9, 2025 at 8:30am – 5:00pm CET
Session: Poster - MASLD: Experimental and pathophysiology
Preclinical
Abstract #: 2105
Title: Next generation hepatitis B virus antisense oligonucleotides incorporating novel chemistries demonstrated significantly improved properties compared to current clinical candidates
Presenter: Jin Hong, PhD
Date/Time: May 9, 2025 at 8:30am – 5:00pm CET
Session: Poster - Viral Hepatitis: Experimental and pathophysiology
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 10, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inizioevoke.com
FAQ
What are the key findings from ALG-000184's 96-week study for chronic HBV infection?
How effective is Aligos Therapeutics' ALG-055009 in treating MASH patients?
What makes ALG-000184 potentially first-in-class for HBV treatment?
How many presentations will ALGS feature at EASL Congress 2025?
